Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Früh

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
EJNMMI Research|April 10, 2020
Radiation dosimetry of <sup>18</sup>F-AzaFol: A first in-human use of a folate receptor PET tracerSilvano Gnesin, Joachim Müller, Irene A Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
BMC Cancer|October 8, 2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancerMartin Sebastian, Alexandros Papachristofilou, Christian Weiss, et al.
Cancer Immunology, Immunotherapy : CII|April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortSabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2022
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II studyAlfredo Addeo, Sacha I Rothschild, Lisa Holer, et al.
Journal of Cancer Research and Clinical Oncology|December 7, 2021
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patientsMette-Triin Purde, Rebekka Niederer, Nikolaus B Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient dataAntonio Rossi, Massimo Di Maio, Paolo Chiodini, et al.
Clinical Lung Cancer|June 25, 2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter StudyKira-Lee Koster, Sarvaganthasenay Yohasenan, Ahmet Samil Pakmak, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
EJNMMI Research|April 10, 2020
Radiation dosimetry of <sup>18</sup>F-AzaFol: A first in-human use of a folate receptor PET tracerSilvano Gnesin, Joachim Müller, Irene A Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
BMC Cancer|October 8, 2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancerMartin Sebastian, Alexandros Papachristofilou, Christian Weiss, et al.
Cancer Immunology, Immunotherapy : CII|April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortSabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2022
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II studyAlfredo Addeo, Sacha I Rothschild, Lisa Holer, et al.
Journal of Cancer Research and Clinical Oncology|December 7, 2021
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patientsMette-Triin Purde, Rebekka Niederer, Nikolaus B Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient dataAntonio Rossi, Massimo Di Maio, Paolo Chiodini, et al.
Clinical Lung Cancer|June 25, 2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter StudyKira-Lee Koster, Sarvaganthasenay Yohasenan, Ahmet Samil Pakmak, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Pageof 10